Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright‘s target price indicates a potential upside of 168.46% from the stock’s current price.
Actinium Pharmaceuticals Price Performance
Shares of ATNM stock opened at $1.49 on Tuesday. The company has a market capitalization of $46.85 million, a price-to-earnings ratio of -1.07 and a beta of 0.27. Actinium Pharmaceuticals has a one year low of $0.74 and a one year high of $1.72. The company’s fifty day moving average price is $1.29 and its 200-day moving average price is $1.13.
Institutional Investors Weigh In On Actinium Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Actinium Pharmaceuticals during the second quarter valued at about $388,000. Renaissance Technologies LLC lifted its position in shares of Actinium Pharmaceuticals by 20.7% in the first quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares in the last quarter. Finally, Compass Financial Management LLC purchased a new position in shares of Actinium Pharmaceuticals in the second quarter valued at about $588,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia.
Read More
- Five stocks we like better than Actinium Pharmaceuticals
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
